An investigational selective dopamine norepinephrine reuptake inhibitor has shown promising effects on sleepiness in obstructive sleep apnea (OSA) patients.
Solriamfetol (JZP-110), the trial therapy from Jazz Pharmaceuticals, was tested for its treatment of the common OSA symptom, excessive sleepiness (ES) in a phase 3 trial. The results were published at the 2017 Annual CHEST Meeting in Toronto, ON, CA, this week.
The US-based study, led by Gary K. Zammit, PhD, president and chief executive officer of research organization Clinilabs, sought out JZP-110’s effect on ES in nearly 500 OSA patients. Criteria for the study included adults-only, with current or prior primary OSA treatment use.